GENEVA, SWITZERLAND--(Marketwired - December 15, 2015) - Novimmune, a privately held, Swiss biotech company focused on the discovery and development of antibody-based drugs for the targeted treatment of inflammatory and rare diseases, immune-related disorders and cancer, today announced that the data from the abstract on Hemophagocytic Lymphohistiocytosis (HLH) were presented by Akiko Shimamura, MD, PhD from Boston Children’s Hospital, Boston, MA, at the “Best of ASH” at the end of the 2015 Annual Meeting of the American Society of Hematology in Orlando, Florida on Tuesday, December 8.
The late-breaking abstract reported the preliminary results from Novimmune’s pilot Phase 2 study in children with primary HLH treated with NI-0501, a fully human monoclonal antibody that targets interferon-gamma (IFNγ) and is the first treatment developed specifically for HLH.
During this plenary session, a review of the biggest breakthroughs from the meeting’s more than 4,500 abstract presentations occurred. Following a summary of the study and data, Dr. Akiko Shimamura concluded, “These are exciting preliminary results. Stay tuned.”
“We are honored that our abstract on NI-0501 was selected for the ‘Best of ASH’ session at this year’s Annual Meeting,” said Novimmune Chief Executive Officer Jack Barbut. “To be recognized by ASH for our work in providing treatment options for patients suffering from devastating diseases like HLH is truly satisfying and a testament to the dedication of our team at Novimmune.”
About Novimmune
Novimmune SA is a Swiss biopharmaceutical company focused on the discovery and development of antibody-based drugs for the targeted treatment of inflammatory diseases, immune-related disorders, and cancer. The company is headquartered in Geneva. More information is available on the company website at www.novimmune.com.
Contact:
Jack Barbut
+41 22 839 71 41
Email Contact
